Metformin usage in type 2 diabetes mellitus: Are safety guidelines adhered to?

Internal Medicine Journal

Volumn 44, Issue 3, 2014, Pages 266-272

  Huang, W ^a   Castelino, R L ^a   Peterson, G M ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Contraindication; Inappropriate usage; Metformin; Renal function; Type 2 diabetes mellitus

Indexed keywords

LACTIC ACID; METFORMIN; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; DEHYDRATION; DIABETIC KETOACIDOSIS; DRUG CONTRAINDICATION; DRUG SAFETY; FEMALE; GANGRENE; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICATION COMPLIANCE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; TEACHING HOSPITAL; VERY ELDERLY; YOUNG ADULT; DIABETES MELLITUS, TYPE 2; STANDARDS;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84896837578     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12369     Document Type: Article

References (47)

1. Pharmaceutical benefits schedule item reports. Medicare Australia Statistics. [cited 2013 May 1]. Available from URL: https://www.medicareaustralia.gov.au/statistics/pbs_item.shtml
2. Shenfield G. Metformin: myths, misunderstandings and lessons from history. Aust Prescr 2013; 36: 38-39.
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
6. Runge S, Mayerle J, Warnke C, Robinson D, Roser M, Felix SB etal. Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? Diabetes Obes Metab 2008; 10: 91-93.
7. Tahrani AA, Varughese GI, Scarpello JH, Hanna FW. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 2007; 335: 508-512.
8. Salpeter S, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010: CD002967.
9. Blow O, Magliore L, Claridge JA, Butler K, Young JS. The golden hour and the silver day: detection and correction of occult hypoperfusion within 24 hours improves outcome from major trauma. J Trauma 1999; 47: 964-969.
10. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338: 265-266.
11. Diabetes Australia. Diabetes management in general practice - guidelines for type 2 diabetes 2012/2013. [updated 2013 Apr 08; cited 2013 May 10]. Available from URL: http://www.diabetesaustralia.com.au/Documents/DA/What's%20New/12.10.02%20Diabetes%20Management%20in%20General%20Practice.pdf.
12. Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. 2012. [cited 2012 Jun 20]. Available from URL: http://www.medicinescomplete.com
13. National Institute for Health and Care Excellence. Type 2 diabetes: the management of type 2 diabetes (CG 87). National Institute for Health and Care Excellence. 2009 [updated 2010 Mar; cited 2013 Apr 21]. Available from URL: http://www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf
14. AHFS Drug Information. Metformin hydrochloride. Bethesda: American Society of Health-System Pharmacists. 2013. [cited 2013 Mar 25]. Available from URL: https://www.medicinescomplete.com/mc/ahfs/current/
15. AMH Online. Metformin. Australian Medicines Handbook Pty Ltd. 2013 [cited 2013 May 10]. Available from URL: https://www.amh.net.au/online/view.php?page=chapter10/monographmetformin.html#metformin
16. Glucophage [package insert]. Millers Point NSW: Alphapharm Pty Limited; 2012.
17. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-772.
18. Holstein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point? Diabetologia 2005; 48: 2454-2459.
19. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004; 255: 179-187.
20. Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013; 39: 179-190.
21. Endocrinology Expert Group. Therapeutic Guidelines: Endocrinology, Version 4. Melbourne: Therapeutic Guidelines Limited; 2009.
22. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. Can Med Assoc J 2005; 172: 367-379.
23. Cardiovascular Expert Groups. Therapeutic Guidelines: Cardiovascular, Version 6. Melbourne: Therapeutic Guidelines Limited; 2012.
24. Stacpoole PW. Lactic acidosis. Endocrinol Metab Clin North Am 1993; 22: 221-245.
25. Mizock BA, Falk JL. Lactic acidosis in critical illness. Crit Care Med 1992; 20: 80-93.
26. Seifter JL. Chapter 120, acid-base disorders. In: Goldman L, Schafer AI, eds. Goldman: Goldman's Cecil Medicine, 24th edn. New York: Saunders; 2011; 745-746.
27. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005; 28: 539-543.
28. Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M etal. Frequency of inappropriate metformin prescriptions. JAMA 2002; 287: 2504-2505.
29. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002; 162: 434-437.
30. Holstein A, Nahrwold D, Hinze S, Egberts EH. Contra-indications to metformin therapy are largely disregarded. Diabet Med 1999; 16: 692-696.
31. Kamber N, Davis WA, Bruce DG, Davis TM. Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. Med J Aust 2008; 188: 446-449.
32. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; CD002967.
33. Aguilar C, Reza A, Garcia JE, Rull JA. Biguanide related lactic acidosis: incidence and risk factors. Arch Med Res 1992; 23: 19-24.
34. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988; 37: 1020-1024.
35. Scale T, Harvey JN. Diabetes, metformin and lactic acidosis. Clin Endocrinol 2011; 74: 191-196.
36. Khandwala HM. The prevalence of contraindications to the use of metformin. Can J Diabetes 2004; 28: 380-384.
37. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 2010; 33: 727-740.
38. Bellomo R. Bench-to-bedside review: lactate and the kidney. Crit Care 2002; 6: 322-326.
39. Devetzis V, Passadakis P, Panagoutsos S, Theodoridis M, Thodis E, Georgoulidou A etal. Metformin-related lactic acidosis in patients with acute kidney injury. Int Urol Nephrol 2011; 43: 1243-1248.
40. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Safety 1999; 20: 377-384.
41. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med 2011; 123: 133-143.
42. Warren RE, Strachan MW, Wild S, McKnight JA. Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin. Diabet Med 2007; 24: 494-497.
43. Ekstrom N, Schioler L, Svensson AM, Eeg-Olofsson K, Miao Jonasson J, Zethelius B etal. Effectiveness and safety of metformin in 51675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2012; 2: e001076.
44. Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC etal. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet 2013; 52: 373-384.
45. Duong JK, Roberts DM, Furlong TJ, Kumar SS, Greenfield JR, Kirkpatrick CM etal. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab 2012; 14: 963-965.
46. Sterner G, Elmstahl S, Frid A. Renal function in a large cohort of metformin treated patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2012; 12: 227-231.
47. Norwood DK, Chilipko AA, Amin SM, Macharia D, Still KL. Evaluating the potential benefits of metformin in patients with cardiovascular disease and heart failure. Consult Pharm 2013; 28: 579-583.